William F. Hahne
Corporate Officer/Principal bei BIO-PATH HOLDINGS, INC.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Peter Nielsen | M | 75 | 17 Jahre | |
| Douglas Morris | M | 68 | 17 Jahre | |
| Shaji Procida | F | - |
Eisai, Inc.
 Eisai, Inc. Pharmaceuticals: MajorHealth Technology Eisai, Inc. manufactures pharmaceuticals products. It focuses on neurology, gastrointestinal disorders and oncology critical care. The company was founded in 1995 and is headquartered in Woodcliff Lake, NJ. | 26 Jahre |
| Michael Tardugno | M | 73 | 17 Jahre | |
| Anthony Price | M | - | 10 Jahre | |
| Heath Cleaver | M | 51 | 10 Jahre | |
| Paul Aubert | M | 54 | 6 Jahre | |
| Ana Tari Ashizawa | M | - | 17 Jahre | |
| Aline Sherwood | F | 54 | 2 Jahre | |
| Michael Roberts | M | - | 10 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Anthony P. Deasey | M | 74 | 7 Jahre | |
| Lawrence Olanoff | M | 72 | 1 Jahre | |
| Yim-Pan Cheung | M | 77 | 24 Jahre | |
| Jonathan Rothberg | M | 60 |
CuraGen Corp.
 CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | 11 Jahre |
| Mark P. Colonnese | M | 68 | 2 Jahre | |
| Ulrich W. Mueller | M | 57 | 3 Jahre | |
| Pok Yu Chow | M | 71 | 16 Jahre | |
| Martina Molsbergen | F | 59 | 3 Jahre | |
| Michael Garrison | M | 54 | 5 Jahre | |
| Amy P. Sing | M | 65 | 3 Jahre | |
| John E. Murphy | M | 76 |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | 4 Jahre |
| William Ho | M | 48 |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | - |
| Claude Tihon | M | - | - | |
| Paul B. Susie | M | 56 | 1 Jahre | |
| Nicholas Borys | M | 64 | 16 Jahre | |
| Michael McKenna | M | 61 |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | 10 Jahre |
| Mark Italia | M | - | - | |
| Rajeev Chillakuru | M | - |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | 5 Jahre |
| William J. Lambert | M | 65 |
Eisai, Inc.
Eisai, Inc. Pharmaceuticals: MajorHealth Technology Eisai, Inc. manufactures pharmaceuticals products. It focuses on neurology, gastrointestinal disorders and oncology critical care. The company was founded in 1995 and is headquartered in Woodcliff Lake, NJ. | 9 Jahre |
| Mary E. Taylor | F | 65 |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | 5 Jahre |
| Kimberly Muller | F | - |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | 3 Jahre |
| Xi Ming Li | M | 63 |
Eisai, Inc.
Eisai, Inc. Pharmaceuticals: MajorHealth Technology Eisai, Inc. manufactures pharmaceuticals products. It focuses on neurology, gastrointestinal disorders and oncology critical care. The company was founded in 1995 and is headquartered in Woodcliff Lake, NJ. | 2 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 32 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- William F. Hahne
- Persönliches Netzwerk
